QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=CE2049D0E55AC0DF318C4A9DF0DF865C;jsessionid=2D454D7F5CD07B99BE8D7281BAFFBF85;jsessionid=4392441200BEE4A81D6BF1744FB4CCEF;jsessionid=1C1E8BEBE8322BF1A687431788BE879D;jsessionid=E998095C1DD684055B8DFBDBE7984CF6;jsessionid=DB40433D716EF7E769DEA329AB1FEE9E;jsessionid=5FE67B83972C8F85645880FE3D364C98 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=CE2049D0E55AC0DF318C4A9DF0DF865C;jsessionid=2D454D7F5CD07B99BE8D7281BAFFBF85;jsessionid=4392441200BEE4A81D6BF1744FB4CCEF;jsessionid=1C1E8BEBE8322BF1A687431788BE879D;jsessionid=E998095C1DD684055B8DFBDBE7984CF6;jsessionid=DB40433D716EF7E769DEA329AB1FEE9E;jsessionid=5FE67B83972C8F85645880FE3D364C98